EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

N-Nitrosodimethylamine investigations in Muta™Mouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations

Anthony M Lynch iD, Jonathan Howe, Deon Hildebrand, James S Harvey, Mark Burman, Danielle S G Harte, Liangfu Chen, Casey Kmett, Wei Shi, Charles F McHugh, Kinnari K Patel, Venkat Junnotula und 3 weitere

Mutagenesis · 2024

DOI: 10.1093/mutage/geae001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mutagenesis, 2024. Verfasst von Anthony M Lynch und 14 weiteren Autor:innen. Beteiligte Einrichtung: Genetic Toxicology & Photosafety, GSK R&D, Stevenage, SG1 2NY, United Kingdom. Hauptthemen laut MEDLINE: Dimethylnitrosamine, Mutagens. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The N-nitrosamine, N-nitrosodimethylamine (NDMA), is an environmental mutagen and rodent carcinogen. Small levels of NDMA have been identified as an impurity in some commonly used drugs, resulting in several product recalls. In this study, NDMA was evaluated in an OECD TG-488 compliant Muta™Mouse gene mutation assay (28-day oral dosing across seven daily doses of 0.02-4 mg/kg/day) using an integrated design that assessed mutation at the transgenic lacZ locus in various tissues and at the endogenous Pig-a gene-locus, along with micronucleus frequencies in peripheral blood. Liver pathology was determined together with NDMA exposure in blood and liver. The additivity of mutation induction was assessed by including two acute single-dose treatment groups (i.e. 5 and 10 mg/kg dose on Day 1), which represented the same total dose as two of the repeat dose treatment groups. NDMA did not induce statistically significant increases in mean lacZ mutant frequency (MF) in bone marrow, spleen, bladder, or stomach, nor in peripheral blood (Pig-a mutation or micronucleus induction) when tested up to 4 mg/kg/day. There were dose-dependent increases in mean lacZ MF in the liver, lung, and kidney following 28-day repeat dosing or in the liver and kidney after a single dose (10 mg/kg). No observed genotoxic effect levels (NOGEL) were determined for the positive repeat dose–response relationships. Mutagenicity did not exhibit simple additivity in the liver since there was a reduction in MF following NDMA repeat dosing compared with acute dosing for the same total dose. Benchmark dose modelling was used to estimate point of departure doses for NDMA mutagenicity in Muta™Mouse and rank order target organ tissue sensitivity (liver > kidney or lung). The BMD50 value for liver was 0.32 mg/kg/day following repeat dosing (confidence interval 0.21–0.46 mg/kg/day). In addition, liver toxicity was observed at doses of ≥ 1.1 mg/kg/day NDMA and correlated with systemic and target organ exposure. The integration of these results and their implications for risk assessment are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DimethylnitrosamineMutagensMutationDNA DamageMutagenesis

Stichwörter der Autor:innen

Benchmark dose modellingMuta™Mouse gene mutation assayN-NitrosodimethylamineN-nitrosaminepoint of departure

Substanzen

DimethylnitrosamineMutagens

Autor:innen und Institutionen

  • Genetic Toxicology & Photosafety, GSK R&D, Stevenage, SG1 2NY, United Kingdom.
  • Pathology, GSK R&D, Stevenage, SG1 2NY, United Kingdom.
  • DMPK, GSK R&D, Upper Providence, Collegeville, PA, United States.
  • BIB, GSK R&D, Upper Providence, Collegeville, PA, United States.
  • TPPS, GSK R&D, Stevenage, SG1 2NY, United Kingdom.
  • RosettaPath Ltd, Hertford, United Kingdom.

ORCID-Profile: Anthony M Lynch, Richard Haworth

Zitieren

APA

Lynch, A. M., Howe, J., Hildebrand, D., Harvey, J. S., Burman, M., Harte, D. S. G., Chen, L., Kmett, C., Shi, W., McHugh, C. F., Patel, K. K., Junnotula, V., Kenny, J., Haworth, R., & Wills, J. W. (2024). N-Nitrosodimethylamine investigations in Muta™Mouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations. Mutagenesis. https://doi.org/10.1093/mutage/geae001

Vancouver

Lynch AM, Howe J, Hildebrand D, Harvey JS, Burman M, Harte DSG, et al. N-Nitrosodimethylamine investigations in Muta™Mouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations. Mutagenesis. 2024. doi:10.1093/mutage/geae001

BibTeX
@article{Lynch2024,
  author = {Lynch, Anthony M and Howe, Jonathan and Hildebrand, Deon and Harvey, James S and Burman, Mark and Harte, Danielle S G and Chen, Liangfu and Kmett, Casey and Shi, Wei and McHugh, Charles F and Patel, Kinnari K and Junnotula, Venkat and Kenny, Julia and Haworth, Richard and Wills, John W},
  title = {N-Nitrosodimethylamine investigations in Muta™Mouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations},
  journal = {Mutagenesis},
  year = {2024},
  doi = {10.1093/mutage/geae001}
}
Kostenlos starten →